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SUMMARY
SETTING—Multidrug-resistant tuberculosis (MDR-TB) patients lost to follow-up (LTFU) from 
Programmatic Management of Drug-resistant Tuberculosis facilities in the Philippines.
OBJECTIVES—To gain insight into patients’ readiness to return to treatment.
METHODS—MDR-TB patients who initiated treatment and were categorized as LTFU were 
identified using TB registers, contacted, and asked to consent to an interview and medical record 
review. At the conclusion of the interview, patients’ readiness to restart treatment was assessed and 
examined in relation to demographic, clinical, and interview data. Odds ratios were calculated.
RESULTS—When asked if they would consider restarting MDR-TB treatment, 3% of the 89 
participating patients reported that they had already restarted, 34% indicated that they wanted to 
restart, 33% had not considered restarting, 28% were undecided, and 2% had decided against 
restarting. Patients who wanted to restart treatment were more likely to report having borrowed 
money for TB-related expenses (OR 5.97, 95%CI 1.27– 28.18), and were less likely to report 
being self-employed (OR 0.08, 95%CI 0.01–0.67), or perceive themselves at low or no risk for TB 
relapse (OR 0.30, 95%CI 0.08–0.96) than patients who did not indicate an interest in restarting 
treatment.
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CONCLUSIONS—Efforts to re-engage LTFU patients in care should consider financial barriers, 
knowledge gaps, and personal adherence challenges in patients.
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patient decision; readiness; health behavior; stages of change; patient education
Multidrug-resistant tuberculosis (MDR-TB), defined by the World Health Organization 
(WHO) as tuberculosis (TB) caused by bacteria resistant to at least isoniazid and rifampin 
(RMP), the two most powerful first-line anti-tuberculosis drugs, presents a major threat to 
the control of TB in the Philippines. According to WHO estimates, 2% (n = 4400) of new 
TB cases and 21% (n = 4100) of TB retreatment cases are MDR-TB.1 Moreover, drug 
resistance has been detected in all regions of the country.2
Programmatic Management of Drug-resistant Tuberculosis (PMDT) activities have been led 
by the Philippines Department of Health since 2009. The scale-up of PMDT activities has 
required concerted effort and significant resources. However, lost to follow-up (LTFU) rates 
have incrementally increased with the scale-up, and may undermine these efforts. In the 
2011 PMDT patient cohort, 39% of the 1185 patients enrolled on MDR-TB treatment were 
LTFU, i.e., patients whose treatment was interrupted for at least 2 consecutive months.3
Persuading LTFU patients to return to treatment can help reduce mortality, prevent further 
spread of MDR-TB, and inhibit the development and transmission of more extensively drug-
resistant strains of bacteria.4–6 It is therefore crucial to gain insight into factors associated 
with non-adherent patients’ readiness to return to treatment, and develop appropriate 
strategies to re-engage LTFU MDR-TB patients into treatment.
In 2014, the Philippines National Tuberculosis Program conducted a study to assess risk 
factors for being LTFU in MDR-TB patients.7 This study found that LTFU was 
independently associated with alcohol abuse and patients’ higher self-rating of vomiting 
severity. Independent factors protective against LTFU included patients’ receipt of any type 
of assistance from the TB program, better general knowledge about TB, and greater trust in 
and rapport with health care staff.7 We further analyzed the study data to identify and 
describe factors associated with self-reported readiness to restart treatment among LTFU 
MDR-TB patients.
METHODS
The study was approved by the Institutional Review Board of the Tropical Disease 
Foundation (Makati City), the Ethics Review Committee (ERC) of the Lung Center of the 
Philippines (Manila) and the ERC of the Philippine Tuberculosis Society, Inc (Metro 
Manila, The Philippines).
The main study had a case-control design and included adult patients with confirmed MDR 
or RMP-resistant TB, with MDR-TB treatment initiated between 1 July and 31 December 
2012 at 15 MDR-TB treatment facilities with three or more LTFU MDR-TB patients.7 Cases 
were defined as patients who were LTFU from MDR-TB treatment. Controls were defined 
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as patients who were still continuing MDR-TB treatment or with treatment outcomes of 
cured, completed, or failed at the time when the study was conducted.
Patients characterized as LTFU by 1 January 2014 were identified using TB registers. Study 
staff contacted these patients and asked them to provide written consent to an in-depth 
interview and medical record review.
At the conclusion of the interview, study staff assessed each LTFU patient’s readiness to 
restart MDR-TB treatment. To identify each patient’s stage of readiness, an educational 
assessment form was developed based upon the Transtheoretical Model (TTM) and 
Precaution Adoption Process Model (PAPM).8,9 These theoretical models recognize 
behavior change as a process that can be categorized into stages of readiness.8,9 Both 
theoretical models include a stage in which a person has no intention of making a change 
because they are unaware of or under-informed about the consequences of their actions, a 
stage in which a person is undecided what to do as they are aware of the benefits and 
drawbacks associated with a change, a stage in which a person is planning to act, a stage in 
which a person is taking action, and a stage in which a person works to maintain a behavior. 
The PAPM includes an additional stage in which a person is aware of risks, yet makes a 
conscious decision not to engage in a recommended course of action.9 In accordance with 
the educational assessment form, study staff first asked each patient if they had ever thought 
about restarting anti-tuberculosis treatment. If the patient answered ‘yes’, they were then 
asked if they had already restarted treatment and to provide the reason for restarting 
treatment. If a patient reported that they had not already restarted treatment, they were read a 
series of statements and asked to identify which of the following statements best described 
their thoughts: 1) ‘I have never thought about restarting TB treatment’, 2) ‘I am undecided 
about restarting TB treatment’, 3) ‘I have decided I do not want to restart TB treatment’, and 
4) ‘I have decided I do want to restart treatment’.
Once a patients’ stage of readiness to restart treatment was assessed and documented, study 
staff relayed an educational message based on TTM and PAPM constructs, tailored to each 
patient’s stage of readiness.
Patients’ stage of readiness was then examined in relation to clinical and demographic data 
obtained through a review of medical records, and interview data focused on knowledge 
about TB, the patient’s relationship with treatment center staff, risk perceptions, and self-
reported reasons for LTFU. For each topic, patients who reported that they wanted to restart 
treatment were compared to patients who did not indicate an interest in restarting treatment 
(those who had not considered, were undecided, or decided against restarting treatment).
Categorical variables were compared using the χ2 test or Fisher’s exact test, as appropriate. 
Univariate odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. We used 
α = 0.05 to determine statistical significance. Statistical analyses were performed using SAS 
software, version 9.3 (SAS Institute Inc, Cary, NC, USA).
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A total of 136 LTFU MDR-TB patients who had received care at 15 of the 44 PMDT centers 
in the country were eligible for study inclusion.7 In this group, 41 patients were not found, 4 
refused participation, 91 were enrolled, and 89 (98%) responded to the questions included 
on the educational assessment form (Appendix Figure A*). Of these 89 participants, 65% 
were male, the median age was 43 years (range 18–67), 53% were married or cohabiting, 
74% had high school education or lower, 53% were residing in urban slum areas, and 43% 
were employed at the time of the interview; medical records documented that 94% were 
living at or below the poverty line, all had pulmonary disease, and 95% had one or more 
previous TB episodes noted in their medical record (Table 1).
Readiness to restart treatment
When asked if they had considered restarting MDR-TB treatment, 3 (3%) reported they had 
already restarted after developing TB symptoms again, 30 (34%) stated they wanted to 
restart, 29 (33%) had not considered restarting, 25 (28%) were undecided, and 2 (2%) stated 
they had decided against restarting treatment (Appendix Figure A).
As shown in Appendix Table A, among the 86 patients who had not restarted MDR-TB 
treatment, no differences were detected between the group who reported wanting to restart 
treatment (n=30) and the group who did not (n = 56) in terms of sex; civil status; level of 
education; location of residence; socio-economic level; changes to employment status during 
anti-tuberculosis treatment; number of previous TB episodes; outcome of previous TB 
episodes; comorbid conditions; and tobacco, alcohol, and drug use.
LTFU MDR-TB patients who wanted to restart treatment were significantly more likely to 
report that they or their family had borrowed money to cover costs associated with their TB 
illness than those who did not indicate an interest in restarting treatment (91.7% vs. 64.8%, 
OR 5.97, 95%CI 1.27–28.18). Patients who wanted to restart treatment were significantly 
less likely to report that they were self-employed than patients who did not indicate an 
interest in restarting treatment (3.3% vs. 29.1%, OR 0.08, 95%CI 0.01–0.67).
Patients who considered restarting treatment were more likely to report that they were 
unable to work (26.7% vs. 10.9%, OR 2.97, 95%CI 0.92–9.59) or were out of work and 
looking for work (36.7% vs. 17.9%, OR 2.66, 95%CI 0.97–7.31), and less likely to report 
that they were responsible for the household budget (23.3% vs. 42.9%, OR 0.41, 95%CI 
0.14– 1.10) than patients who did not indicate an interest in restarting treatment; however, 
these associations did not reach statistical significance.
Table 2 summarizes the data collected during interviews to identify reasons for being 
recorded as LTFU during MDR-TB treatment with regard to patients’ decision about 
restarting MDR-TB treatment. No statistically significant relationships were found between 
*The appendix is available in the online version of this article, at http://www.ingentaconnect.com/content/iuatld/ijtld/
2016/00000020/00000009/art00016
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their readiness to restart treatment and patient’s knowledge about TB, relationship with 
treatment center staff, or self-reported reasons for LTFU. However, 46.7% of those who 
wanted to restart treatment reported medication side effects or fear of side effects as a 
personal reason for LTFU compared to 66.1% of those who did not indicate an interest in 
restarting treatment (OR 0.45, 95%CI 0.18–1.13), suggesting that side effects are a major 
adherence challenge and that the efficient management of side effects should be a high-
ranking program priority.
When risk perceptions were examined, 13.3% of those who wanted to restart treatment 
thought they had little to no chance of a TB relapse compared to 33.9% of those who did not 
want to restart treatment (OR 0.30, 95%CI 0.08–0.96). How frequently patients worried 
about a TB relapse or transmitting TB to loved ones, and understanding that a relapse may 
be harder to cure, was not associated with readiness to restart.
DISCUSSION
Of the 89 LTFU patients included in this study, only three (3%) had restarted MDR-TB 
treatment, and all three noted that their motivation for restarting was because they had 
become ill again. Among the remainder of the group, more than half did not indicate 
readiness to restart their treatment. We found that only three factors were significantly 
associated with patients’ decision regarding restarting treatment: self-employment, having 
borrowed money to cover costs due to TB illness, and greater perceived susceptibility 
towards a TB relapse. These data, examined in context with the socio-economic status of the 
entire cohort and all self-reported reasons for LTFU, indicate that economic factors influence 
LTFU patients’ decision-making processes. Specifically, these patients may not want to risk 
loss of income, or are unwilling to draw resources away from the household to pursue 
treatment. The data also illustrate the importance of a patient-centered approach, 10,11 with 
attention to adherence challenges, when developing a plan to re-engage LTFU MDR-TB 
patients into treatment or to prevent LTFU.
Reports in the literature demonstrate that enablers such as transportation assistance and food 
packages7,12 help patients minimize or overcome financial barriers to adherence. In the 
Philippines, transportation assistance, food assistance, and temporary housing is available to 
patients after initiating treatment.7,13 Table 3 outlines services available to enable adherence 
when participants are undergoing treatment. As noted, the amount of assistance is limited, 
and as reported elsewhere, patients often incur transportation expenses due to fares that 
exceed the allotted amount, housing costs after moving away from family to be closer to 
treatment centers, and loss of income when undergoing directly observed therapy (DOT) at 
treatment centers that are open for a limited number of hours each day.4,7,14 Achieving 
program targets and improving patient outcomes among persons living slightly above, at, or 
below the poverty line may require services that enable patients and their families to 
preserve their capacity to earn income, keep what they earn to meet basic needs, and retain 
their possessions. To accomplish this may require operating DOT programs in a manner that 
accommodates work or school schedules, providing financial aid to those too sick to work, 
eliminating out-of-pocket expenses for transportation to and from clinic-based DOT sites by 
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providing full transportation costs, offering community-based DOT, and delivering 
assistance without delay.
Additional approaches include screening for early identification of medication side effects, 
prompt access to medical care, and well-managed treatment for a range of medication side 
effects at no cost. In the Philippines, although medications to manage side effects are 
available at no cost, the formulary of available medications is limited, and during interviews 
participants reported out-of-pocket costs for medical care for side effects. These experiences 
may have influenced patients’ readiness to restart treatment.
Finally, these data illustrate the need for robust patient education. Almost a third of the 
LTFU MDR-TB patients interviewed felt they had no chance or very little chance of 
becoming ill with TB again. However, 95.5% of these patients had experienced one or more 
TB episodes prior to their most recent diagnosis. These responses, coupled with personal 
relapse experiences, call into question how well patients understand the disease process and 
whether TB is differentiated from other lung infections such as pneumonia.
These responses also emphasize the need for patient education that extends beyond a simple 
explanation of the diagnosis and treatment. Additional educational topics may include the 
rationale for treatment duration, medication side effects, common problems that arise during 
treatment and how these may be addressed, available assistance, risks associated with MDR-
TB treatment non-adherence, and consequences of non-adherence on multiple facets of 
people’s lives.
The educational messages provided to patients incorporated some of these topics. Crafted in 
accordance with TTM and PAPM constructs, the messages differed slightly based upon 
patient’s self-reported readiness to restart treatment.8,9,15 For example, the educational 
message for patients who had not considered restarting treatment focused on the individual’s 
susceptibility to relapse of TB following LTFU, information on risk factors, encouragement 
that the patient consider their own negative experiences while ill and the personal advantages 
of returning to treatment. The message for patients who were undecided about restarting 
treatment or had decided against restarting treatment emphasized the likelihood and 
potential seriousness of a TB relapse, recommendations of global TB experts, patient’s fears 
or worries, the benefits of restarting treatment, and how to take action.
Interventions based on stage-based theories have demonstrated positive behavioral 
outcomes;16,17 however, the educational messages provided to LTFU patients were not 
systematically evaluated during development to determine understanding and acceptability 
in the target population, nor was the effect of these messages on treatment return assessed, as 
the study timeline and resources could not accommodate these evaluations. Nevertheless, the 
creation of messages such as these requires additional study as part of the effort to prevent 
loss to follow-up or reengage LTFU TB patients with TB care.7
Additional study limitations include a relatively small sample size, limited statistical power, 
and reliance on participants’ understanding and candid self-report of their readiness to return 
to treatment. Social desirability bias may have had an influence on participants’ responses, 
leading them to respond with socially appropriate answers instead of their true thoughts and 
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experiences. Despite these limitations, this study provides insights into factors that may 
motivate or impede LTFU patients’ return to treatment.
CONCLUSIONS
LTFU patients’ understanding of TB relapse is one factor that may influence their decision 
to restart and complete MDR-TB treatment. Economic factors such as self-employment, 
retaining employment, and the need to borrow money when seeking treatment may also 
influence this decision process. Identifying additional factors as well as interventions that 
positively influence LTFU patients’ treatment reinitiation requires further assessment to 
determine best practices to optimize return and retention. However, efforts to retain patients 
in care through patient enablers, effective management of medication side effects at no cost, 
and outreach immediately following missed doses may be more effective than expending 
efforts to re-engage LTFU patients.
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Study population. * Study exclusion criteria were incarceration, age <18 years, enrollment in 
pharmaceutical clinical trials, and major psychiatric disorder or physical incapacitation. † 
Controls who did not provide consent were replaced by other randomly selected eligible 
patients. MDR-TB = multidrug-resistant TB; LTFU =lost to follow-up; TB = tuberculosis.
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treatment (n = 
56) (Col %)‡ OR (95%CI) P value
Sex
 Male 56 22 (73.3) 34 (60.7) 1.78 (0.67–4.7) 0.24
 Female 30 8 (26.7) 22 (39.3) 1.00
Civil status
 Single, separated, widowed 42 15 (50) 27 (48.2) 1.07 (0.44–2.61) 0.87
 Married, cohabiting 44 15 (50) 29 (51.8) 1.00
Education
 No formal schooling/elementary/
high school
64 21 (70) 43 (76.8) 0.71 (0.26–1.91) 0.49
 College/graduate school 22 9 (30) 13 (23.2) 1.00
Place of residence
 Urban area 25 8 (29.6) 17 (39.5) 0.64 (0.23–1.8) 0.40
 Urban slum 45 19 (70.4) 26 (60.5) 1.00
 Rural area 15 3 (13.6) 12 (31.6) 0.34 (0.08–1.38) 0.12
 Urban slum 45 19 (86.4) 26 (68.4) 1.00
Socio-economic level§
 Living below the poverty line 
(Category C)
81 29 (96.7) 52 (92.9) 2.23 (0.24–20.91) 0.47
 Living above or at the poverty line 
(Category A or B)
5 1 (3.3) 4 (7.1) 1.00
Changes to employment status during anti-tuberculosis treatment¶
 Paid employment before starting 
anti-tuberculosis treatment; had to 
quit/was too sick to work
34 15 (88.2) 19 (76) 2.37 (0.42–13.46) 0.32
 Paid employment before starting 
anti-tuberculosis treatment; still 
employed at my job
8 2 (11.8) 6 (24) 1.00
 Paid employment before starting 
anti-tuberculosis treatment; was fired 
or asked to take a leave of absence
5 1 (33.3) 4 (40) 0.75 (0.05–11.31) 0.84
 Paid employment before starting 
anti-tuberculosis treatment; still 
employed at my job
8 2 (66.7) 6 (60) 1.00
Responses to questions related to employment status at time of interview
 Employed for wages 0.37
  Yes 19 5 (16.7) 14 (25) 0.6 (0.19–1.87)
  No 67 25 (83.3) 42 (75) 1.00
 Self-employed 0.005
  Yes 17 1 (3.3) 16 (29.1) 0.08 (0.01–0.67)
  No 68 29 (96.7) 39 (70.9) 1.00
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treatment (n = 
56) (Col %)‡ OR (95%CI) P value
 Out of work, and looking for work 0.06
  Yes 21 11 (36.7) 10 (17.9) 2.66 (0.97–7.31)
  No 65 19 (63.3) 46 (82.1) 1.00
 Out of work, but not currently looking for work 0.87
  Yes 22 8 (26.7) 14 (25) 1.09 (0.4–3)
  No 64 22 (73.3) 42 (75) 1.00
 Homemaker 0.73
  Yes 22 7 (23.3) 15 (26.8) 0.83 (0.3–2.34)
  No 64 23 (76.7) 41 (73.2) 1.00
 Student 0.46
  Yes 1 0 1 (1.8) 0
  No 85 30 (100) 55 (98.2) 1.00
 Retired 0.29
  Yes 2 0 2 (3.6) 0
  No 84 30 (100) 54 (96.4) 1.00
 Unable to work 0.06
  Yes 14 8 (26.7) 6 (10.9) 2.97 (0.92–9.59)
  No 71 22 (73.3) 49 (89.1) 1.00
Financial responsibility in the household
 Head of the household# 0.19
  Yes 34 9 (30.0) 25 (44.6) 0.53 (0.20–1.37)
  No 52 21 (70.0) 31 (55.4) 1.00
 In charge of the household budget 0.07
  Yes 31 7 (23.3) 24 (42.9) 0.41 (0.14–1.10)
  No 55 23 (76.7) 32 (57.1) 1.00
Financial burden of diagnosis**
 Patient or family sold belongings or household items to help pay expenses during anti-tuberculosis 
treatment
0.57
  Yes 26 10 (34.5) 16 (28.6) 1.32 (0.5–3.44)
  No 59 19 (65.5) 40 (71.4) 1.00
 Patient or family borrowed money to cover costs due to TB illness 0.01
  Yes 57 22 (91.7) 35 (64.8) 5.97 (1.27–28.18)
  No 21 2 (8.3) 19 (35.2) 1.00
Number of previous TB episodes 0.35
 ≤1 46 14 (46.7) 32 (57.1) 0.66 (0.27–1.62)
 ≥2 40 16 (53.3) 24 (42.9) 1.00
Outcome of previous TB episode
 Failure 0.51
  Yes 18 7 (50) 11 (39.3) 1.55 (0.42–5.63)
  Cured/completed 24 7 (50) 17 (60.7) 1.00
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treatment (n = 
56) (Col %)‡ OR (95%CI) P value
 LTFU 0.14
  Yes 13 7 (50) 6 (26.1) 2.83 (0.7–11.51)
  Cured/completed 24 7 (50) 17 (73.9) 1.00
 Unknown 0.88
  Yes 29 9 (56.3) 20 (54.1) 1.09 (0.34–3.56)
  Cured/completed 24 7 (43.8) 17 (45.9) 1.00
 New case 0.37
  Yes 2 0 2 (10.5) 0
  Cured/completed 24 7 (100) 17 (89.5) 1.00
Comorbidities††
 Diabetes mellitus 0.72
  Yes 20 6 (21.4) 14 (25) 0.82 (0.28–2.43)
  No 64 22 (78.6) 42 (75) 1.00
 HIV/AIDS 0.48
  Yes 1 0 1 (1.8) 0
  No 83 28 (100) 55 (98.2) 1.00
 Kidney disease 1.00
  Yes 3 1 (3.6) 2 (3.6) 1 (0.09–11.52)
  No 81 27 (96.4) 54 (96.4) 1.00
 Other lung disease 0.37
  Yes 6 1 (3.6) 5 (8.9) 0.38 (0.04–3.4)
  No 78 27 (96.4) 51 (91.1) 1.00
 Other comorbid conditions 1.00
  Yes 6 2 (7.1) 4 (7.1) 1 (0.17–5.82)
  No 78 26 (92.9) 52 (92.9) 1.00
Risk factors††
 Current or past tobacco smoking 0.61
  Yes 60 21 (75) 39 (69.6) 1.31 (0.47–3.65)
  Never 24 7 (25) 17 (30.4) 1.00
 Current or past alcohol abuse 0.54
  Yes 61 21 (77.8) 40 (71.4) 1.4 (0.48–4.11)
  Never 22 6 (22.2) 16 (28.6) 1.00
 Current or past drug use 0.87
  Yes 18 6 (23.1) 12 (21.4) 1.1 (0.36–3.35)
  Never 64 20 (76.9) 44 (78.6) 1.00
*
Number of patients with available data or responses for each response category.
†
Percentages were calculated for columns. The column denominator was 30 unless participants provided a response to a 
characteristic that was compared with a referent group or data were not available.
‡
Percentages were calculated for columns. The column denominator was 56 unless participants provided a response to a 
characteristic that was compared with a referent group or data were not available.
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Data obtained from medical records. Class A indicates individuals living above the poverty line, Class B individuals living 
at the poverty line, and Class C individuals living below the poverty line. The poverty line was equivalent to a per capita 
income of 16 841 Philippine peso a year.1
¶
Of 47 patients who had paid employment before starting treatment, 34 indicated they subsequently ‘had to quit’ and 5 
reported that they had subsequently been ‘fired/asked to take leave of absence’.
#
Defined as the family member who provided for more than half of household costs in the year before TB diagnosis.2,3
**
One participant refused to respond to the question regarding selling of household goods, and eight participants refused to 
respond or did not know the answer to the question regarding money borrowed.
††
Data on comorbidities, tobacco use, and alcohol abuse were available for 84 study participants. Data on drug use were 
available for 82 study participants.
OR = odds ratio; CI = confidence interval; TB = tuberculosis; LTFU = lost to follow-up; HIV = human immunodeficiency 
virus; AIDS= acquired immune-deficiency syndrome.
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Table 1
Demographic characteristics of MDR-TB patients lost to follow-up whose readiness to restart treatment was 
assessed (n = 89).
n (%)
Sex
 Male 58 (65.2)
 Female 31 (34.8)
Age, years
 <20 4 (4.5)
 20–29 18 (20.2)
 30–39 15 (16.9)
 40–49 30 (33.7)
 ≥50 22 (24.7)
Civil status
 Single, separated, widowed 42 (47.2)
 Married, cohabiting 47 (52.8)
Education
 No formal schooling/elementary/high school 66 (74.2)
 College/graduate school 23 (25.8)
Residence
 Rural area 15 (16.9)
 Urban slum 47 (52.8)
 Urban area 26 (29.2)
 Unknown 1 (1.1)
Socio-economic level
 Living below the poverty line (Class C) 84 (94.4)
 Living above or at the poverty line (Class A and B) 5 (5.6)
Employment status
 Unemployed 33 (37.1)
 Employed 38 (42.7)
 Other (retired, student, disabled, housewife) 12 (13.5)
 Unknown 6 (6.7)
Site of disease
 Pulmonary 89 (100)
 Extra-pulmonary 0 (0)
Number of previous TB episodes
 None 1 (1.1)
 One 45 (50.6)
 Two or more 40 (44.9)
 Unknown 3 (3.4)
MDR-TB = multidrug-resistant TB; TB = tuberculosis.
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Table 3
Program services to enable treatment adherence available to MDR-TB patients in the Philippines at the time of 
this study
• Anti-tuberculosis medicines provided to patients at no cost
• Medications to manage adverse events provided to patients at no cost (limited formulary)
• TB diagnostic tests provided to patients at no cost
• Fixed amount provided for transportation costs (funds provided retrospectively, based upon adherence to appointments)
• Temporary housing located near PMDT treatment centers for patients from rural areas (limited availability)
• 44 PMDT treatment centers located throughout the country, to provide comprehensive MDR-TB services
• Patient education (non-standardized)
• Patient support groups (located within some facilities)
• Food basket incentives (limited availability)
• Small monetary bonus provided to patients at 6, 12, and 18 months, if fully adherent during each 6-month period
TB = tuberculosis; MDR-TB = multidrug-resistant TB; PMDT = programmatic management of drug-resistant TB.
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